Peripheral arterial thrombosis following administration of infliximab for Crohn disease

Infliximab is one of the most widely used tumour necrosis factor-alpha (TNF-) inhibitors for control of Crohn disease. We report the case of a patient with ileocolonic Crohn disease developing major arterial thrombosis after treatment with infliximab. After conservative management and infliximab withdrawal, thrombus dissolution and vessel recannalisation were observed. Few cases of arterial thrombosis following infliximab treatment have been documented; continued vigilance in the reporting of adverse events of biological therapy is required given the development of newer biological agents.